Fecal Zonulin as an Early Predictor of Necrotizing Enterocolitis in Premature Infants: A Pilot Prospective Single-Center Cohort Study
This pilot prospective study demonstrates that elevated fecal zonulin levels on postnatal day 7 serve as a promising noninvasive biomarker for predicting the early development of necrotizing enterocolitis in premature infants, warranting further validation in larger multicenter trials.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the delicate early days of life, a newborn's body is a landscape of rapid change, but for babies born too soon, the journey is fraught with hidden dangers. One of the most serious threats they face is a condition called necrotizing enterocolitis, a severe illness where the lining of the intestine becomes inflamed and begins to die. This condition is particularly devastating because it strikes when the infant's gut is still immature and struggling to function. The key to understanding this danger lies in the intestinal barrier, a thin, protective wall made of cells that lines the inside of the gut. This wall acts as a gatekeeper, allowing nutrients to pass through while keeping harmful bacteria and toxins locked inside the digestive tract. When this wall is weak or damaged, its gates open too wide, letting dangerous substances leak out and trigger a violent immune response that can destroy the tissue. Scientists have long known that this breakdown happens before the baby shows any obvious signs of sickness, but finding a way to spot the weakness early has been a difficult challenge.
Researchers in Tashkent, Uzbekistan, set out to find a new way to see this invisible damage before it becomes a crisis. They focused on a specific protein called zonulin, which acts like a switch for the intestinal wall. When zonulin levels rise, it signals that the tight seals between the gut cells are loosening, making the barrier more permeable. The team wanted to know if measuring the amount of zonulin in a baby's stool could predict who would develop necrotizing enterocolitis before the disease actually started. They followed a group of 91 premature infants, born between 22 and 32 weeks of gestation, along with a smaller group of 25 healthy babies born at full term. Over the first two weeks of life, the researchers collected stool samples on the third, seventh, and fourteenth days after birth to measure the levels of zonulin and other markers of inflammation.
The results revealed a clear and telling pattern. In the healthy, full-term babies, the amount of zonulin in their stool rose gradually over the first two weeks, a normal part of development as their guts matured. However, the premature babies showed much higher levels of zonulin from the very beginning, reflecting the natural immaturity of their intestinal barriers. More importantly, the researchers found that among the premature infants, those who would later develop necrotizing enterocolitis had significantly higher levels of zonulin on the seventh day of life compared to those who remained healthy. On that specific day, the average level in the babies who got sick was 618.4 nanograms per milliliter, while the healthy babies averaged 343.5 nanograms per milliliter. This difference appeared several days before any clinical symptoms of the disease were visible, suggesting that the intestinal barrier was already failing before the illness became apparent.
To see how well this measurement could predict the disease, the team analyzed the data to find a specific threshold. They determined that a zonulin level of 490 nanograms per milliliter on the seventh day was a strong indicator. Using this cutoff, the test correctly identified 85 percent of the babies who would go on to develop the condition, while correctly ruling out 72 percent of those who would not. This performance was notably better than other common markers used to detect gut inflammation, such as C-reactive protein or fecal calprotectin, which tend to rise only after the inflammation has already begun. The study suggests that zonulin offers a unique window into the health of the gut barrier, detecting the problem at a stage when the tissue is still intact but vulnerable, rather than waiting for the damage to become severe.
The researchers were careful to note that their findings come from a single hospital and a relatively small number of cases, with only ten infants developing the disease. Because of this limited size, they described their statistical models as exploratory, meaning the results are promising but need to be confirmed by larger studies across different centers. They also acknowledged that the specific test they used might detect proteins similar to zonulin, which requires caution when interpreting the exact numbers. Despite these limitations, the study provides a compelling new direction for neonatal care. It supports the idea that the breakdown of the intestinal barrier is an early event in the development of necrotizing enterocolitis and that measuring zonulin in stool could serve as a non-invasive tool to identify the most vulnerable infants. If future research validates these results, doctors could potentially use this information to monitor at-risk babies more closely or intervene earlier, potentially preventing the severe tissue damage that currently makes this condition so dangerous.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.